DekaBank Deutsche Girozentrale Has $5.61 Million Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)

DekaBank Deutsche Girozentrale lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,540 shares of the biopharmaceutical company’s stock after selling 7,588 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Alnylam Pharmaceuticals were worth $5,607,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of ALNY. FMR LLC raised its position in shares of Alnylam Pharmaceuticals by 0.4% during the 2nd quarter. FMR LLC now owns 15,078,361 shares of the biopharmaceutical company’s stock worth $1,485,068,000 after purchasing an additional 52,653 shares during the last quarter. BB Biotech AG raised its position in shares of Alnylam Pharmaceuticals by 20.2% during the 3rd quarter. BB Biotech AG now owns 1,370,538 shares of the biopharmaceutical company’s stock worth $119,949,000 after purchasing an additional 230,000 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Alnylam Pharmaceuticals by 49.4% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,356,408 shares of the biopharmaceutical company’s stock worth $133,593,000 after purchasing an additional 448,362 shares during the last quarter. First Trust Advisors LP raised its position in shares of Alnylam Pharmaceuticals by 42.0% during the 3rd quarter. First Trust Advisors LP now owns 937,025 shares of the biopharmaceutical company’s stock worth $82,008,000 after purchasing an additional 277,259 shares during the last quarter. Finally, American Century Companies Inc. raised its position in shares of Alnylam Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 615,220 shares of the biopharmaceutical company’s stock worth $53,844,000 after purchasing an additional 187,480 shares during the last quarter. Institutional investors and hedge funds own 90.63% of the company’s stock.

Several research analysts recently weighed in on ALNY shares. Cowen restated a “buy” rating and set a $157.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 2nd. Chardan Capital restated a “buy” rating and set a $180.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 3rd. BMO Capital Markets restated a “buy” rating and set a $127.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 3rd. B. Riley upped their price target on shares of Alnylam Pharmaceuticals from $210.00 to $230.00 and gave the stock a “buy” rating in a research report on Monday, August 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $152.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, August 13th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $138.44.

Shares of NASDAQ ALNY opened at $80.61 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $63.57 and a 12-month high of $153.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.96 and a current ratio of 11.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. The business had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $22.66 million. During the same period in the prior year, the company posted ($1.34) EPS. The firm’s revenue was down 87.9% on a year-over-year basis. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -7.65 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “DekaBank Deutsche Girozentrale Has $5.61 Million Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/11/30/dekabank-deutsche-girozentrale-has-5-61-million-holdings-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Read More: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply